Sun Pharma Advanced Research Company (SPARC) has secured a Rare Pediatric Disease Priority Review Voucher (PRV) associated with the approval of Sezaby from United States Food and Drug Administration (USFDA). A PRV is a tradable voucher granted by the USFDA to encourage the development of new treatments for rare pediatric diseases, that can be redeemed to receive a priority review for a subsequent, separate drug application. The company intends to utilize the voucher to further accelerate its pipeline.
Sun Pharma Advanced Research Company is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery.
